ATE537839T1 - Impfstoff zum schutz gegen staphylococcus aureus auf der basis zellwandassoziierter proteine - Google Patents

Impfstoff zum schutz gegen staphylococcus aureus auf der basis zellwandassoziierter proteine

Info

Publication number
ATE537839T1
ATE537839T1 AT07107512T AT07107512T ATE537839T1 AT E537839 T1 ATE537839 T1 AT E537839T1 AT 07107512 T AT07107512 T AT 07107512T AT 07107512 T AT07107512 T AT 07107512T AT E537839 T1 ATE537839 T1 AT E537839T1
Authority
AT
Austria
Prior art keywords
staphylococcus aureus
cell wall
vaccine
protection against
associated proteins
Prior art date
Application number
AT07107512T
Other languages
English (en)
Inventor
Martin Kroenke
Oleg Krut
Eva Glowalla
Bettina Tosetti
Original Assignee
Martin Kroenke
Oleg Krut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martin Kroenke, Oleg Krut filed Critical Martin Kroenke
Application granted granted Critical
Publication of ATE537839T1 publication Critical patent/ATE537839T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT07107512T 2007-05-04 2007-05-04 Impfstoff zum schutz gegen staphylococcus aureus auf der basis zellwandassoziierter proteine ATE537839T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07107512A EP1987836B1 (de) 2007-05-04 2007-05-04 Impfstoff zum Schutz gegen staphylococcus aureus auf der Basis zellwandassoziierter Proteine

Publications (1)

Publication Number Publication Date
ATE537839T1 true ATE537839T1 (de) 2012-01-15

Family

ID=38895836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07107512T ATE537839T1 (de) 2007-05-04 2007-05-04 Impfstoff zum schutz gegen staphylococcus aureus auf der basis zellwandassoziierter proteine

Country Status (3)

Country Link
US (1) US20080299127A1 (de)
EP (3) EP2374467B1 (de)
AT (1) ATE537839T1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2638058B1 (de) * 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase-peptid-konjugat-impfstoffe gegen staphylococcus aureus
EP2773370A4 (de) 2011-10-31 2016-09-28 Merck Sharp & Dohme Schutzimpfstoff auf grundlage des staphylococcus aureus-proteins sa2451
US9376487B2 (en) 2012-07-10 2016-06-28 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2493 protein
EP3363459A1 (de) 2017-02-17 2018-08-22 Alexander Klimka Polypeptid-epitope von s. aureus und entsprechende monoklonale antikörper zur behandlung von infektionen und immundiagnose
CN114088946B (zh) * 2021-07-02 2024-03-29 中国科学技术大学 转录调控因子WalR和MgrA的亚硝基化修饰在治疗金黄色葡萄球菌感染中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
JP4404627B2 (ja) * 2001-08-02 2010-01-27 ユニヴァーシティー オヴ シェフィールド 抗原性ポリペプチド
HRP20100240T1 (hr) * 2003-07-24 2010-09-30 Merck Sharp & Dohme Corp. Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus
AU2005287505A1 (en) * 2004-09-22 2006-03-30 Biosynexus Incorporated Staphylococcal immunogenic compositions

Also Published As

Publication number Publication date
EP2374467B1 (de) 2013-08-28
EP1987836A1 (de) 2008-11-05
EP2374466A1 (de) 2011-10-12
US20080299127A1 (en) 2008-12-04
EP2374466B1 (de) 2013-08-28
EP1987836B1 (de) 2011-12-21
EP2374467A1 (de) 2011-10-12

Similar Documents

Publication Publication Date Title
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
BRPI0813455A2 (pt) Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado.
LT3444261T (lt) Metilbardoksolono 2,2-difluorpropionamido darinys, jo farmacinės kompozicijos ir polimorfai, skirti panaudoti tam tikrų ligų gydymui
NO20092104L (no) Nye 1,2-dihydroquinolinderivater, farmasøytisk sammensetning inneholdende slike, samt anvendelse derav
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
EP2475649A4 (de) Indenonderivat und pharmazeutische zusammensetzung damit
ATE536373T1 (de) Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität
FR2915199B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
UA107550C2 (uk) Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів
ATE537839T1 (de) Impfstoff zum schutz gegen staphylococcus aureus auf der basis zellwandassoziierter proteine
UA115232C2 (uk) Препарат, що містить аморфний емодепсид
DK1939204T3 (da) Kondenseret heterocyklisk derivat, medicinalsammensætning indeholdende samme og medicinsk anvendelse deraf
BRPI0820985A2 (pt) Composto derivado de 5-aminociclometil-oxazondin-2-ona, medicamento e composição farmacêutica que os contém e uso dos mesmos
WO2008146172A3 (en) Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans
BRPI0809143A2 (pt) polimorfismos genéticos associados com eventos coronários e resposta a fármaco, métodos de detecção e usos dos mesmos
FR2938537B1 (fr) Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
DE602005020693D1 (de) Verpackung für pharmazeutische, medizinische oder ähnliche produkte, besonders pestizide oder pflanzenschutzprodukte
EP2264031A4 (de) Neuartiges benzoxazin-benzimidazol-derivat, pharmazeutische zusammensetzung damit und verwendung davon
EP2322505A4 (de) 1-adamantylazetidin-2-on-derivat, herstellung davon und pharmazeutisches präparat damit
BRPI0813937A2 (pt) Derivado de 17beta-ciano-19-nor-andros-4-eno, seu uso e medicamentos contendo o derivado
EP2402333A4 (de) 1,4-benzothiazepin-1-oxidderivat und pharmazeutische zusammensetzung damit